Xtandi Shows Activity in Men with Prostate Cancer Resistant to Chemotherapy and Zytiga
Since its FDA approval in 2011 FDA abiraterone (Zytiga) has supplanted docetaxel (chemotherapy), other than perhaps Provenge, as preferred first-line treatment for metastatic castrate-resistant prostate cancer. August 2012 saw the FDA approval of enzalutamide (Xtandi) [...]
Circulating Tumor Cell Enumeration in Metastatic Neuroendocrine Prostate Cancer and Castration-Resistant Prostate Cancer
An uncommon, but very aggressive form of prostate cancer is known as Neuroendocrine prostate cancer (NEPC). It is generally accepted that Circulating Tumor Cell (CTC) counts as measured by CellSearch (a method to catch and [...]
Denosumab for the Prevention of Skeletal Events in Men with Castration-Resistant Advanced Prostate Cancer
From: the 2014 ASCO GU Meeting Abstract No: 35 Researchers have found in a randomized controlled trial of men with metastatic castration-resistant prostate cancer (mCRPC) the use of the treatment denosumab was superior to the [...]
From ASCO GU – Long Term Data Show Ra-223 Safe in Advanced Prostate Cancer
The novel radiopharmaceutical radium-223 (Xofigo) appears to have long term safety with minimal adverse events. In an updated report, given at ASCO GU, on the ALSYMPCA trial of radium-233 (Xofigo), the researchers have found that [...]
Zytiga in Québec, Radium-223 in England & Lets Change Our Antiquated Approval Nonsense
Men with metastatic castration-resistant prostate cancer (mCRPC) in Québec, Canada now have access to Zytiga (abiraterone acetate) prior to having chemotherapy. Effective February 3, 2014, the province has added ZYTIGA to the public drug formulary [...]
Correcting the NICE Guidance for Xtandi – It is worse for Men with Progressive Advanced Prostate Cancer
After a great deal of confusion and what turned out to be an error on my part I wish to let you know that the NICE (The U.K.’s National Institute for Health and Care Excellence) [...]